Our Current Clinical Trials

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver condition worldwide, strongly linked to obesity, insulin resistance, and abnormal lipid metabolism. In its progressive form, non-alcoholic steatohepatitis (NASH), it can lead to cirrhosis, liver failure, or hepatocellular carcinoma.

Despite its high prevalence, there are limited approved therapies. Current management relies on lifestyle changes, but many patients require additional targeted interventions.

This clinical trial aims to evaluate the efficacy of new therapeutic approaches in reducing hepatic fat, improving liver function, and preventing progression to advanced liver disease.

Hypothyroidism is one of the most common endocrine disorders, affecting millions worldwide. It is characterized by inadequate thyroid hormone production, which can lead to fatigue, weight gain, slowed metabolism, dyslipidemia, and impaired quality of life.

While standard therapy with levothyroxine effectively normalizes thyroid hormone levels in most patients, many continue to experience symptoms or metabolic complications.

This trial is designed to assess whether alternative can improve thyroid function, metabolic outcomes, and patient-reported well-being beyond current standard care.

Plantar fibromatosis, also known as Ledderhose disease, is a rare but often debilitating condition caused by the formation of fibrous nodules within the plantar fascia of the foot.

It is considered a benign fibroproliferative disorder but can cause pain, reduced mobility, and significant impairment in daily activities.

Currently, there is no widely accepted standard treatment, and options such as surgery, steroid injections, and radiation carry varying risks of recurrence and complications.

This clinical trial seeks to explore novel therapies that target fibroblast activity and reduce fibrotic tissue growth, with the goal of providing more effective and lasting relief for patients.